

Supplementary Table 2. Baseline demographics and characteristics in subgroup of patients given sequential administrations of contrast media

Variable	Total patients	PC-AKI (-) group	PC-AKI (+) group	p-value
No. of patients	139	101	38	
Demographics				
Age (yr)	63 (49–73)	64 (50–74)	62 (48–73)	0.99
Body mass index (kg/m ²)	23.0 (21.1–24.9)	23.1 (21.1–24.9)	23.0 (21.1–26.2)	0.99
Male sex	90 (64.7)	64 (63.4)	26 (68.4)	0.56
Preexisting illnesses				
Hypertension	55 (39.6)	41 (40.6)	14 (36.8)	0.85
Diabetes	36 (25.9)	23 (22.8)	13 (34.2)	0.19
Liver disease	18 (12.9)	13 (12.9)	5 (13.2)	>0.99
Chronic kidney disease	8 (5.6)	5 (5.0)	3	0.68
Pulmonary disease	7 (5.0)	4 (4.0)	3 (7.9)	0.39
Congestive heart failure	7 (5.0)	4 (4.0)	3 (7.9)	0.39
Ischemic heart disease	22 (15.8)	14 (13.9)	8 (21.1)	0.31
Cerebrovascular disease	17 (12.2)	14 (13.9)	3 (7.9)	0.40
Charlson comorbidity index	3 (1–5)	3 (1–5)	4 (1–5)	0.69
Medication				
ACEi or ARB	2 (4.3)	1 (1.0)	1 (2.6)	0.47
Allopurinol	1 (0.7)	0	1 (2.6)	0.27
Diuretics	8 (5.7)	7 (6.9)	1 (2.6)	0.45
NSAIDs	37 (26.4)	28 (27.7)	9 (23.7)	0.83
Metformin	3 (2.1)	2 (2.0)	1 (2.6)	>0.99
Acyclovir	2 (1.4)	2 (2.0)	0	>0.99
TB medication (rifampin)	1 (0.7)	1 (1.0)	0	>0.99
Antibiotics				
Aminoglycoside	1 (0.7)	0	1 (2.6)	0.27
Cephalosporins	24 (17.1)	15 (14.9)	9 (23.7)	0.22
Fluoroquinolone	4 (2.9)	4 (4.0)	0	0.57
Vancomycin	2 (1.4)	2 (2.0)	0	>0.99
Chief complaint at ED visit				
Trauma	45 (32.4)	33 (32.7)	11 (28.9)	0.62
Neurologic	47 (33.8)	35 (34.7)	12 (31.6)	
Cardiac arrest	7 (5.0)	5 (5.0)	2 (5.3)	
Vital sign at ED visit				
Mean arterial pressure (mmHg)	91.0 (77.0–107.0)	92.0 (77.5–106.5)	88.0 (75.0–107.3)	0.91
Pulse rate (beats/min)	87.0 (72.0–104.0)	86.0 (72.0–102.0)	94.0 (76.3–111.0)	0.20
Respiratory rate (beats/min)	20.0 (20.0–22.0)	20.0 (20.0–22.0)	20.0 (20.0–24.0)	0.65
Body temperature (°C)	36.7 (36.2–37.4)	36.8 (36.2–37.5)	36.6 (36.2–37.0)	0.30
SpO ₂ (%)	97.0 (96.0–98.0)	98.0 (96.0–98.0)	97.0 (95.0–98.0)	0.27
Laboratory data at ED visit				
White blood cell (×10 ³ /μL)	9.5 (7.3–14.2)	9.8 (7.3–14.4)	9.1 (8.0–12.1)	0.40
Hemoglobin (g/dL)	13.1 (11.0–14.4)	13.2 (11.2–14.4)	12.8 (9.9–14.8)	0.87
Hematocrit (%)	37.9 (33.1–42.0)	37.8 (33.1–41.9)	38.0 (33.4–43.3)	0.95
Platelet (×10 ³ /μL)	217.0 (146.0–264.0)	226.0 (167.5–281.5)	180.0 (130.8–247.5)	0.03
Osmolality (mOsmol/kg)	296.2 (285.0–308.0)	291.0 (283.0–305.1)	303.1 (295.0–316.5)	<0.01
Na (mEq/L)	139.2 (136.6–142.0)	138.8 (136.2–140.8)	142.1 (138.9–146.3)	<0.01

(Continued to the next page)

Supplementary Table 2. Continued

Variable	Total patients	PC-AKI (-) group	PC-AKI (+) group	p-value
K (mEq/L)	4.0 (3.7–4.2)	4.0 (3.7–4.2)	4.0 (3.8–4.3)	0.83
Cl (mEq/L)	104.1 (99.0–109.2)	103.3 (99.0–108.1)	106.2 (98.0–110.5)	0.04
Glucose (mg/dL)	119.0 (94.0–170.0)	114.0 (92.0–154.5)	152.0 (110.8–227.0)	<0.01
Albumin (g/dL)	3.8 (3.3–4.1)	3.8 (3.3–4.2)	3.7 (3.4–4.1)	0.42
BUN (mg/dL)	17.7 (14.0–23.0)	17.6 (14.0–22.5)	17.9 (13.6–25.5)	0.77
Creatinine (mg/dL)	0.9 (0.7–1.1)	0.8 (0.6–1.0)	1.0 (0.8–1.3)	0.07
eGFR (mL/min/1.73 m ²)	93.1 (71.2–107.1)	94.0 (74.5–109.4)	86.3 (65.5–103.6)	0.09
CRP (mg/dL)	2.3 (0.6–8.6)	2.2 (0.6–8.6)	2.5 (0.6–8.6)	>0.99
Lactate (mEq/L)	2.5 (1.5–4.1)	2.4 (1.4–3.9)	3.0 (2.0–4.5)	0.22
Fluid balance (mL/hr)				
Input	130.0 (75.9–235.6)	119.2 (74.2–212.6)	158.6 (80.3–303.9)	0.24
Output	77.7 (42.3–117.8)	76.0 (40.0–115.8)	79.4 (49.4–138.3)	0.70
Volume of contrast media (mL)				
First iodine-based contrast media	110.8 (100.0–130.0)	112.2 (100.0–130.0)	106.0 (100.0–138.0)	0.69
Second gadolinium-based contrast agent	6.2 (5.3–7.0)	6.3 (5.5–7.2)	6.1 (5.2–6.9)	0.52
Time interval between CT and MRI (hr)	3.6 (1.5–6.5)	4.6 (2.2–8.0)	1.8 (1.0–3.4)	<0.01
Survival discharge	132 (95.0)	96 (95.0)	36 (94.7)	>0.99

Data are expressed as number only, median (interquartile range), or number (%).

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; CRP, C-reactive protein; CT, computed tomography; ED, emergency department; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance image; NSAIDs, nonsteroidal anti-inflammatory drugs; PC-AKI, post-contrast acute kidney injury; SpO₂, oxygen saturation; TB, tuberculosis.